Identification for biomarkers of skin lesions and lupus nephritis in patients with systemic lupus erythematosus

XIA Yuan-rui; FAN Yin-guang; FANG Xin-yu; YE Dong-qing

doi:10.16462/j.cnki.zhjbkz.2021.08.011

Volume 25 Issue 8

Aug. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(8): 928-934

XIA Yuan-rui, FAN Yin-guang, FANG Xin-yu, YE Dong-qing. Identification for biomarkers of skin lesions and lupus nephritis in patients with systemic lupus erythematosus[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(8): 928-934. doi: 10.16462/j.cnki.zhjbkz.2021.08.011

Citation:

XIA Yuan-rui, FAN Yin-guang, FANG Xin-yu, YE Dong-qing. Identification for biomarkers of skin lesions and lupus nephritis in patients with systemic lupus erythematosus[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(8): 928-934. doi: 10.16462/j.cnki.zhjbkz.2021.08.011

Citation:

PDF( 1134 KB)

Identification for biomarkers of skin lesions and lupus nephritis in patients with systemic lupus erythematosus

doi: 10.16462/j.cnki.zhjbkz.2021.08.011

Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei 230032, China

Funds:

National Natural Science Foundation of China 82073652

National Natural Science Foundation of China 81872693

National Natural Science Foundation of China 81673258

More Information

Corresponding author: YE Dong-qing, E-mail: anhuiydq@126.com
Received Date: 2021-04-10
Rev Recd Date: 2021-06-13

Available Online: 2021-08-24

Publish Date: 2021-08-10

Abstract

Abstract

Objective To explore protein biomarkers of skin lesions and lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE), so as to provide evidence for diagnosis and control of the SLE. Methods High-throughput protein chip technology was used to identify serum protein biomarkers for SLE, and the biomarkers were analyzed individually and jointly for the two complications of skin lesions and LN to find the best diagnostic indicators. Results The separate indicators transcription factor 5 (SP5), ribosomal protein L7a (RPL7A) and combined panel of (RPL7A +small nuclear ribonucleoprotein polypeptide C(SNRPC)) had the highest diagnostic value between skin lesions group and its control group. Compared with non-LN group, SP5 and (SP5+ribosomal protein L35(RPL35)) had the highest diagnostic value in LN group. Conclusion SP5 can be used as a protein biomarker for diagnosis of skin lesions and LN in SLE patients.
- Systemic lupus erythematosus,
- Skin lesions,
- Lupus nephritis,
- Biomarkers

FullText(HTML)

References(24)

References

[1]	Cozzani E, Drosera M, Gasparini G, et al. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects[J]. Autoimmune Dis, 2014(2014): 321359. DOI: 10.1155/2014/321359.
[2]	Ferreira TAR, de Andrade HM, de Pádua PM, et al. Identification of potential biomarkers for systemic lupus erythematosus diagnosis using two-dimensional differential gel electrophoresis (2D-DIGE) and mass spectrometry[J]. Autoimmunity, 2017, 50(4): 247-256. DOI: 10.1080/08916934.2017.1344975.
[3]	Kazemipour N, Qazizadeh H, Sepehrimanesh M, et al. Biomarkers identified from serum proteomic analysis for the differential diagnosis of systemic lupus erythematosus[J]. Lupus, 2015, 24(6): 582-587. DOI: 10.1177/0961203314558860.
[4]	Wu T, Ding H, Han J, et al. Antibody-array-based proteomic screening of serum markers in systemic lupus erythematosus: a discovery study[J]. J Proteome Res, 2016, 15(7): 2102-2114. DOI: 10.1021/acs.jproteome.5b00905.
[5]	Qi S, Chen Q, Xu D, et al. Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis[J]. Lupus, 2018, 27(10): 1582-1590. DOI: 10.1177/0961203318773643.
[6]	Tedeschi SK, Johnson SR, Boumpas D, et al. Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration[J]. Arthritis Care Res (Hoboken), 2018, 70(4): 571-581. DOI: 10.1002/acr.23317.
[7]	Sinha AA, Dey-Rao R. Genomic investigation of lupus in the skin[J]. J Investig Dermatol Symp Proc, 2017, 18(2): 75-80. DOI: 10.1016/j.jisp.2016.09.002.
[8]	Larosa M, laccarino L, Gatto M, et al. Advances in the diagnosis and classification of systemic lupus erythematosus[J]. Expert Rev Clin Immunol, 2016, 12(12): 1309-1320. DOI: 10.1080/1744666X.2016.1206470.
[9]	Ling HZ, Xu SZ, Leng RX, et al. Discovery of new serum biomarker panels for systemic lupus erythematosus diagnosis[J]. Rheumatology (Oxford), 2020, 59(6): 1416-1425. DOI: 10.1093/rheumatology/kez634.
[10]	Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9): 1725. DOI: 10.1002/art.1780400928.
[11]	Grankvist K, Gomez R, Nybo M, et al. Preanalytical aspects on short- and long-term storage of serum and plasma[J]. Diagnosis (Berl), 2019, 6(1): 51-56. DOI: 10.1515/dx-2018-0037.
[12]	Zhang YP, Wu J, Han YF, et al. Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema[J]. Autoimmun Rev, 2017, 16(7): 735-742. DOI: 10.1016/j.autrev.2017.05.009.
[13]	Misra R, Gupta R. Biomarkers in lupus nephritis[J]. Int J Rheum Dis, 2015, 18(2): 219-232. DOI: 10.1111/1756-185X.12602.
[14]	Esdaile JM, Abrahamowicz M, Joseph L, et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus, Why some tests fail[J]. Arthritis Rheum, 1996, 39(3): 370-378. DOI: 10.1002/art.1780390304.
[15]	Julkunen H, Ekblom-Kullberg S, Miettinen A. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4[J]. Rheumatol Int, 2012, 32(8): 2445-2451. DOI: 10.1007/s00296-011-1962-3.
[16]	Suske G, Bruford E, Philipsen S. Mammalian SP/KLF transcription factors: bring in the family[J]. Genomics, 2005, 85(5): 551-556. DOI: 10.1016/j.ygeno.2005.01.005.
[17]	Kennedy MW, Chalamalasetty RB, Thomas S, et al. Sp5 and Sp8 recruit beta-catenin and Tcf1-Lef1 to select enhancers to activate Wnt target gene transcription[J]. Proc Natl Acad Sci USA, 2016, 113(13): 3545-3550. DOI: 10.1073/pnas.1519994113.
[18]	Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future[J]. Curr Opin Rheumatol, 2005, 17(5): 550-557. DOI: 10.1097/01.bor.0000172798.26249.fc.
[19]	Fu J, Hsu W. Epidermal Wnt controls hair follicle induction by orchestrating dynamic signaling crosstalk between the epidermis and dermis[J]. J Invest Dermatol, 2013, 133(4): 890-898. DOI: 10.1038/jid.2012.407.
[20]	Gudjonsson JE, Johnston A, Stoll SW, et al. Evidence for altered Wnt signaling in psoriatic skin[J]. J Invest Dermatol, 2010, 130(7): 1849-1859. DOI: 10.1038/jid.2010.67.
[21]	Tveita A, Rekvig OP, Zykova SN. Glomerular matrix Metalloproteinases and their regulators in the pathogenesis of lupus nephritis[J]. Arthritis Res Ther, 2008, 10(6): 229. DOI: 10.1186/ar2532.
[22]	He W, Dai C, Li Y, et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis[J]. J Am Soc Nephrol, 2009, 20(4): 765-776. DOI: 10.1681/ASN.2008060566.
[23]	Szodoray P, Nakken B, Barath S, et al. Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders[J]. Hum Immunol, 2013, 74(12): 1510-1518. DOI: 10.1016/j.humimm.2013.08.003.
[24]	Wang XD, Huang XF, Yan QR, et al. Aberrant activation of the WNT/beta-catenin signaling pathway in lupus nephritis[J]. PLoS One, 2014, 9(1): e84852. DOI: 10.1371/journal.pone.0084852.